Methods and Designs of Modern Breast Cancer Confirmatory Trials

Simple Summary The benefit–risk assessments of new drugs for breast cancer (BC) face several challenges, as all stakeholders do not agree on the evidence bar required for market authorization, and by the fragmentation of breast cancer diagnosis. In this study, we describe the methods and designs of breast cancer confirmatory trials published between 2001 and 2020. We found that the quality of the evidence supporting new breast cancer drugs was improving over time, but that patient-relevant endpoints such as survival and quality of life remained unfrequently used as primary endpoints. Abstract Background: The benefit–risk assessments of new drugs for breast cancer (BC) face several challenges, as all stakeholders do not agree on the evidence bar required for market authorization, and by the fragmentation of breast cancer diagnosis. The aim of this study was to describe the changes in methods and designs of breast cancer confirmatory trials. Methods: All phase III randomized trials published between 2001 and 2020 and assessing systemic BC therapies were included. Trials’ main characteristics, endpoints, and statistical methods were collected using a standardized data extraction form. Results: A total of 347 randomized controlled trials (RCTs) met the inclusion criteria. While most older trials (79%) included all subtypes of breast cancer, most recent trials populations were limited to one large intrinsic BC subgroup (69%). The use of gatekeeping testing strategies increased dramatically from 9% to 71%. The use of overall survival (OS) as an endpoint in the trials increased over time, but its use as a primary endpoint remained infrequent. The inclusion of OS testing in a hierarchical sequence in case of positive testing of a tumor-centered or composite endpoint appeared to have become the new standard. Conclusion: Our findings indicate some improvements in the quality of the evidence-base supporting new breast cancer drugs. The rigorous assessment of patient-relevant endpoints has increased over time, but this improvement is mainly related to the analysis of OS as a secondary endpoint analyzed in a hierarchical sequence.

[1]  E. Winer,et al.  Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Kesselheim,et al.  Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs , 2020, EClinicalMedicine.

[3]  P. Fasching,et al.  Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. , 2019, The New England journal of medicine.

[4]  M. Taphoorn,et al.  Current state of quality of life and patient-reported outcomes research. , 2019, European journal of cancer.

[5]  P. Neven,et al.  The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 , 2019, JAMA oncology.

[6]  Vinay Prasad,et al.  An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. , 2019, JAMA internal medicine.

[7]  A. Kesselheim,et al.  Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. , 2019, JAMA internal medicine.

[8]  J. Doctor,et al.  The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers , 2019, MDM policy & practice.

[9]  E. Perez,et al.  Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. , 2019, The Lancet. Oncology.

[10]  M. Stockler,et al.  Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer , 2018, JNCI cancer spectrum.

[11]  H. Naci,et al.  Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 , 2017, British Medical Journal.

[12]  C. Booth,et al.  Approvals in 2016: questioning the clinical benefit of anticancer therapies , 2017, Nature Reviews Clinical Oncology.

[13]  Elias Mossialos,et al.  Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines , 2017, JAMA oncology.

[14]  F. Fiteni,et al.  Surrogate end points for overall survival in breast cancer trials: A review. , 2016, Breast.

[15]  S Michiels,et al.  Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Virginia G Kaklamani,et al.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.

[17]  C. Davis Drugs, cancer and end-of-life care: A case study of pharmaceuticalization? , 2015, Social science & medicine.

[18]  M. Ellis,et al.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. , 2015, The New England journal of medicine.

[19]  J. Cylus,et al.  Raising the bar for market authorisation of new drugs , 2012, BMJ : British Medical Journal.

[20]  G. Pond,et al.  Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. , 2012, Journal of the National Cancer Institute.

[21]  A. Kesselheim,et al.  Reputation and precedent in the bevacizumab decision. , 2011, The New England journal of medicine.

[22]  M. Buyse,et al.  Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Buyse,et al.  Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.